$95 Million

Milestone Pharmaceuticals, Inc.

Initial Public Offering

Bookrunner, May 2019

Milestone Pharmaceuticals, Inc. is a late-stage biopharmaceutical company developing its Phase III product candidate, etripamil, for the treatment of cardiovascular indications.